Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
REGULATORY
Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
Quick Look: Three NMEs are set for approval review by a key health ministry panel on March 2: Haihe’s risovalisib, MSD’s doravirine/islatravir, and Daiichi Sankyo’s MMR vaccine. The session will also cover label expansions for Enhertu, Nubeqa, Dupixent, and Trodelvy,…
To read the full story
Related Article
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Pfizer Seeks Wider Label for PARP Inhibitor Talzenna in Japan
May 8, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
April 28, 2025
- Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
- Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
- Xocova Filed for Post-Exposure Prophylaxis for COVID-19 in Japan
March 28, 2025
- Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
REGULATORY
- Japan Weighs Possible Approval Revocation for Tavneos, Action Against Kissei
October 22, 2026
- Hernexeos, Rinvoq, Tukysa Label Expansions Now in Line for Japan Approval
October 22, 2026
- LDP, Ishin Resume Social Security Talks, Chuikyo Reform to Follow
October 22, 2026
- LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
- Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…